877402-43-2

Basic information

• Product Name: tert-Butyl 3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-carboxylate
• Synonyms: tert-Butyl 3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-carboxylate
• CAS NO: 877402-43-2
• Molecular Formula: C₁₁H₁₅F₃N₄O₂
• Molecular Weight: 292.26
• Product Categories: API intermediates
• Mol File: 877402-43-2.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 356.9±52.0 °C(Predicted)
• Appearance: /
• Density: 1.43±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: Dichloromethane, Ethyl Acetate
• PKA: 0.25±0.20(Predicted)
• CAS DataBase Reference: tert-Butyl 3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-carboxylate(877402-43-2)
• EPA Substance Registry System: tert-Butyl 3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-carboxylate(877402-43-2)

Safety Data

• Hazardous Substances Data: 877402-43-2(Hazardous Substances Data)

Usage

Description

tert-Butyl 3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-carboxylate is a chemical compound that serves as an intermediate in the synthesis of pharmaceuticals, specifically in the production of Sitagliptin Triazecine Analog (S491015). tert-Butyl 3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-carboxylate belongs to the Sitagliptin family, which has been approved for the treatment of type II diabetes.

Uses

Used in Pharmaceutical Industry:
tert-Butyl 3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine-7(8H)-carboxylate is used as a key intermediate in the synthesis of Sitagliptin Triazecine Analog (S491015) for the treatment of type II diabetes. Its role in the synthesis process is crucial for the development of this therapeutic agent, which helps manage blood sugar levels in patients with this condition.

Upstream product

• 723286-80-4 3-bromo-5,6-dihydro-8H-[1,2,4]triazolo[4,3-a]pyrazine-7-carboxylic acid tert-butyl ester 
• 81290-20-2 (trifluoromethyl)trimethylsilane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 486460-21-3 3-trifluoromethyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine 

Downstream Products

• 1013656-87-5 C₁₈H₂₀F₄N₄O₂ 
• 1013657-17-4 C₂₀H₁₉F₉N₄O₂ 

Relevant articles and documents

Metallaphotoredox Perfluoroalkylation of Organobromides

Ruppert-Prakash type reagents (TMSCF3, TMSC2F5, and TMSC3F7) are readily available, air-stable, and easy-to-handle fluoroalkyl sources. Herein, we describe a mild, copper-catalyzed cross-coupling of these fluoroalkyl nucleophiles with aryl and alkyl bromides to produce a diverse array of trifluoromethyl, pentafluoroethyl, and heptafluoropropyl adducts. This light-mediated transformation proceeds via a silyl-radical-mediated halogen atom abstraction pathway, which enables perfluoroalkylation of a broad range of organobromides of variable steric and electronic demand. The utility of the method is demonstrated through the late-stage functionalization of several drug analogues.

FUSED TRIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel fused triazole derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ("DPP-IV inhibitors") and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.